Basilea has made a solid start to the first half of 2016, with anti-microbial agents Cresemba and Zevtera continuing their respective European roll-outs. Ongoing dialogue with the FDA on the SPA protocol for Zevtera’s Phase III US clinical trial programme means US trials should initiate in H117. Together, these underpin the current valuation with upside potential from further partnering deals for Cresemba, Zevtera and the early-stage oncology pipeline, which in itself is making progress
30 Aug 2016
Moving on up
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Moving on up
Basilea Pharmaceutica AG (BSLN:SWX) | 0 0 0.0%
- Published:
30 Aug 2016 -
Author:
Dr Susie Jana -
Pages:
7
Basilea has made a solid start to the first half of 2016, with anti-microbial agents Cresemba and Zevtera continuing their respective European roll-outs. Ongoing dialogue with the FDA on the SPA protocol for Zevtera’s Phase III US clinical trial programme means US trials should initiate in H117. Together, these underpin the current valuation with upside potential from further partnering deals for Cresemba, Zevtera and the early-stage oncology pipeline, which in itself is making progress